Literature DB >> 26188836

Understanding the Complexities of Cirrhosis.

Andrew J Muir1.   

Abstract

PURPOSE: Cirrhosis and its related complications remain a prominent global health concern despite advances in understanding and treating the disorder. Early diagnosis and intervention strategies may reduce the impact of cirrhosis; however, it can be difficult for initial point-of-care health care providers to identify and refer patients with cirrhosis due to lack of knowledge and resources. This review examines current diagnostic strategies for cirrhosis and cirrhosis-related complications and the potential benefits of multidisciplinary care for patients with the disorder.
METHODS: A PubMed search of the medical literature was conducted to identify current diagnostic methods and standards and ascertain the impact of multidisciplinary care on patients with cirrhosis.
FINDINGS: Screening of patients at risk for cirrhosis has been recommended by several professional and governmental organizations. Unfortunately, identification of early-stage cirrhosis remains challenging despite development of novel calculations for risk (eg, aspartate transaminase-to-platelet count ratio) that use values from common, noninvasive laboratory tests to determine the extent of liver disease. Abnormal liver function test results and alterations in serum liver enzyme markers (eg, alanine and aspartate transaminases) may suggest cirrhosis in patients with chronic liver disease; however, they are not definitive. Liver biopsy is the gold standard for diagnosis and staging of cirrhosis, but its cost, invasiveness, and risk of complications have prompted the development of noninvasive tests (eg, elastography). Primary care physicians should be aware of the signs and symptoms of cirrhosis-related complications, particularly portal hypertension, and refer patients to specialists for further evaluation when warranted. IMPLICATIONS: Patients at risk for cirrhosis should be screened and the underlying etiologic factor(s) of the liver disease treated or appropriately managed when possible. Primary care physicians should be aware of the signs and symptoms of cirrhosis and its related complications and adopt a low threshold for referral to a specialist when the condition is suspected. An integrated, multidisciplinary approach to care between specialists and primary care physicians may improve early detection of cirrhosis and its related complications and strengthen management strategies.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic liver disease; cirrhosis; fibrosis; portal hypertension; primary care

Mesh:

Year:  2015        PMID: 26188836     DOI: 10.1016/j.clinthera.2015.05.507

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  11 in total

Review 1.  Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference-Decompensated cirrhosis: from clinic to transplant.

Authors:  Victor Dong; Maxime Gosselin; Nishita Jagarlamudi; Beverley Kok; Mark G Swain; Jasmohan S Bajaj; Juan G Abraldes; Vladimir Marquez; R Todd Stravitz; Aldo J Montano-Loza; Manuela Merli; Phil Wong; Amanda Brisebois; Puneeta Tandon; Julia Wendon; Scott L Nyberg; François M Carrier; Michael R Lucey; Florence Wong; Jordan J Feld; Constantine J Karvellas; Christopher F Rose; Julien Bissonnette
Journal:  Can Liver J       Date:  2019-12-10

2.  Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.

Authors:  Jeff Y Yang; Andrew M Moon; Hannah Kim; Virginia Pate; A Sidney Barritt; Matthew J Crowley; John B Buse; Til Stürmer; Anastasia-Stefania Alexopoulos
Journal:  J Diabetes Complications       Date:  2020-08-05       Impact factor: 2.852

3.  Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.

Authors:  Ram C Shankaraiah; Elisa Callegari; Paola Guerriero; Alessandro Rimessi; Paolo Pinton; Laura Gramantieri; Enrico M Silini; Silvia Sabbioni; Massimo Negrini
Journal:  Oncogene       Date:  2019-08-13       Impact factor: 9.867

4.  Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model.

Authors:  Daniel Cervantes-Garcia; Adriana Guadalupe Cuellar-Juarez; Gissela Borrego-Soto; Augusto Rojas-Martinez; Liseth Rubi Aldaba-Muruato; Eva Salinas; Javier Ventura-Juarez; Martin Humberto Muñoz-Ortega
Journal:  Mol Med Rep       Date:  2017-10-12       Impact factor: 2.952

5.  Bioelectrical impedance vector analysis evaluates cellularity and hydration in cirrhotic patients.

Authors:  Sabrina Alves Fernandes; Lara Rigon Leonhardt; Daniella Miranda da Silva; Fernanda Donner Alves; Cláudio Augusto Marroni
Journal:  World J Hepatol       Date:  2020-12-27

6.  Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation.

Authors:  Philipp Stoffers; Sabrina Guckenbiehl; Martin Walter Welker; Stefan Zeuzem; Christian Markus Lange; Jonel Trebicka; Eva Herrmann; Christoph Welsch
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

7.  Granulocyte Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit.

Authors:  Cyriac A Philips; Philip Augustine; Sasidharan Rajesh; Rizwan Ahamed; Tom George; Guruprasad Padsalgi; Rajaguru Paramaguru; Gopakumar Valiathan; Solomon K John
Journal:  J Clin Exp Hepatol       Date:  2019-06-01

8.  Patient Views on Advance Care Planning in Cirrhosis: A Qualitative Analysis.

Authors:  Michelle Carbonneau; Tracy Davyduke; Jude Spiers; Amanda Brisebois; Kathleen Ismond; Puneeta Tandon
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-18

9.  Instrument to evaluate the knowledge of patient with cirrhosis on his disease: construction and validity.

Authors:  Mariana Stelmach; Kayo Augusto de Almeida Medeiros; Bárbara Justo Carvalho; Leonardo Zumerkorn Pipek; Gustavo Heluani Antunes de Mesquita; Fernanda Nii; Diego Ramos Martines; Leandro Ryuchi Iuamoto; Luiz Augusto Carneiro D'Albuquerque; Alberto Meyer; Wellington Andraus
Journal:  BMC Gastroenterol       Date:  2021-02-23       Impact factor: 3.067

Review 10.  Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.

Authors:  William R Treem; Melissa Palmer; Isabelle Lonjon-Domanec; Daniel Seekins; Lara Dimick-Santos; Mark I Avigan; John F Marcinak; Ajit Dash; Arie Regev; Eric Maller; Meenal Patwardhan; James H Lewis; Don C Rockey; Adrian M Di Bisceglie; James W Freston; Raul J Andrade; Naga Chalasani
Journal:  Drug Saf       Date:  2020-11-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.